Aurobindo Pharma has announced that its subsidiary, Eugia Pharma Specialities Limited, has received an Official Action Indicated (OAI) classification from the US FDA for its Unit-I manufacturing facility in Shameerpet. This follows an inspection conducted between February 16 and February 27, 2026. The company has confirmed that this regulatory update will have no material impact on its ongoing financial performance or overall manufacturing operations.
Inspection Outcome for Shameerpet Facility
Following a recent site evaluation, the US Food and Drug Administration has classified the Unit-I formulation manufacturing facility, operated by the wholly-owned subsidiary Eugia Pharma Specialities Limited, as Official Action Indicated (OAI). The facility, located in Kolthur Village, Shameerpet Mandal, was inspected by regulators between February 16 and February 27, 2026, resulting in 4 observations.
Financial and Operational Impact
Despite the change in the facility’s classification status, Aurobindo Pharma has formally stated that there is no impact on the company’s financials or business operations. The management remains focused on maintaining high quality-control standards across its global manufacturing network and has committed to keeping stakeholders informed of any future developments regarding this matter.
Source: BSE
